769961-28-6Relevant articles and documents
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors
Potashman, Michele H.,Bready, James,Coxon, Angela,Demelfi Jr., Thomas M.,DiPietro, Lucian,Doerr, Nicholas,Elbaum, Daniel,Estrada, Juan,Gallant, Paul,Germain, Julie,Gu, Yan,Harmange, Jean-Christophe,Kaufman, Stephen A.,Kendall, Rick,Kim, Joseph L.,Kumar, Gondi N.,Long, Alexander M.,Neervannan, Seshadri,Patel, Vinod F.,Polverino, Anthony,Rose, Paul,Van Der Plas, Simon,Whittington, Douglas,Zanon, Roger,Zhao, Huilin
, p. 4351 - 4373 (2008/02/13)
Inhibition of the VEGF signaling pathway has become a valuable approach in the treatment of cancers. Guided by X-ray crystallography and molecular modeling, a series of 2-aminobenzimidazoles and 2-aminobenzoxazoles were identified as potent inhibitors of VEGFR-2 (KDR) in both enzymatic and HUVEC cellular proliferation assays. In this report we describe the synthesis and structure-activity relationship of a series of 2-aminobenzimidazoles and benzoxazoles, culminating in the identification of benzoxazole 22 as a potent and selective VEGFR-2 inhibitor displaying a good pharmacokinetic profile. Compound 22 demonstrated efficacy in both the murine matrigel model for vascular permeability (79% inhibition observed at 100 mg/kg) and the rat corneal angiogenesis model (ED50 = 16.3 mg/kg).
